regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant cholesterol-lowering benefits on top of weight loss—a differentiation strategy aimed at competing with Eli Lilly's and Ozempic Without Muscle Loss? New

For information about supplements that have been investigated in humans for athletic performance and joint health, see our Reviews of Muscle and Workout Supplements , Collagen Supplements , Nitric Oxide Supplements , and Joint Health Supplements

"Compounded semaglutide may carry additional risks and side effects beyond those seen with FDA-approved versions," explains Eapen, MD

Naming confusion: FDA described inconsistent naming around no-DAC, DAC, free-base, and salt forms

Cardiovascular disease Drugs like Ozempic and Wegovy can help reduce the risk of heart attacks , strokes, and other cardiovascular events and improve symptoms of heart failure